Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $30 | In Stock | |
2 mg | $40 | In Stock | |
5 mg | $64 | In Stock | |
10 mg | $89 | In Stock | |
25 mg | $172 | In Stock | |
50 mg | $327 | In Stock | |
100 mg | $486 | In Stock | |
200 mg | $693 | In Stock | |
500 mg | $1,090 | In Stock |
Description | MK-8617 is an orally available HIF PHD1 3 pan-inhibitor, inhibiting PHD1/2/3 (IC50: 1.0/1.0/14 nM). |
Targets&IC50 | PHD1:1 nM, PHD2:1 nM, PHD3:14 nM |
In vitro | In vitro, MK-8617 hasn't markedly inhibitory for CYP1A2, 3A4, 2B6, 2C9, 2C19, or 2D6 (IC50>60 μM), and is a moderate reversible inhibitor of CYP2C8 (IC50: 1.6 μM). MK-8617 (10 μM) is inactive against a general panel of 171 radioligand binding and enzymatic assays. |
In vivo | In liver microsomes (+NADPH) from rat, dog, and monkey, tritiated MK-8617 exhibits minimal metabolic turnover (<10%), but the significant turnover (34%) in HLMs after 60 min (10 μM compound, 1 mg/mL microsomal protein). MK-8617 has good oral bioavailability across species (36?71%), with low clearance and volume of distribution. Increases in circulating reticulocytes are observed at 5 and 15 mg/kg 3 days after challenge and at the 15 mg/kg 4 days after challenge. |
Alias | MK8617 |
Molecular Weight | 443.45 |
Formula | C24H21N5O4 |
Cas No. | 1187990-87-9 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO: 1 mg/ml, Sonication is recommended. ![]() |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.